WHWK — Whitehawk Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
$4.56
-$0.07 (-1.51%)
Whitehawk Therapeutics, Inc. (WHWK) is a biotechnology company listed on NASDAQ. It is led by David J. Lennon Ph.D., based in 2 Headquarters Plaza, Morristown, NJ, United States, 07960, with about 29 employees. Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Latest reported WHWK revenue for 2025-09-30 was $0. Net income was -$17.7M. WHWK currently screens at market cap $202.8M.
Use this WHWK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the WHWK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the WHWK SEC filings page. Lician reads the product cache first so this HTML stays unique to Whitehawk Therapeutics, Inc. even when a live quote feed is slow.
About Whitehawk Therapeutics, Inc.
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
WHWK Key Statistics
Market Cap
$202.76M
Volume
114,756
Previous Close
$5.08
Day Range
$4.83 – $5.10
P/B Ratio
1.75
EPS
-$2.36
Revenue
$25.98M
Net Income
-$63.69M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+6.7%
Profit Margin
-245.1%
Employees
29
WHWK Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $25.98M | $24.35M | $15.22M | $14.00M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$63.69M | -$65.77M | -$60.51M | -$110.09M |
| EPS (Diluted) | -$2.36 | -$2.44 | -$2.69 | -$12.41 |
Total Assets
$70.32M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$28.67M
Operating Cash Flow
-$59.55M
Free Cash Flow
$0.00
Whitehawk Therapeutics, Inc. Company Information
- President, CEO & Director
- David J. Lennon Ph.D.
- Headquarters
- 2 Headquarters Plaza, Morristown, NJ, United States, 07960
- Website
- ir.whitehawktx.com
- Phone
- 551 321 2234
- IPO / Founded
- 2017-08-08
- Sector
- Healthcare
- Industry
- Biotechnology